MEC Plus Full List View

MEC Plus

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains
Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains
Jorge J. García, PharmD, MS, MHA, MBA, FACHE
Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors
Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors
Ashwin Mehta, MD, MPH
Update on Therapy Options for Untreated and Relapsed CLL
Update on Therapy Options for Untreated and Relapsed CLL
Elizabeth Brém, MD
AML: Where Are We Now and Where Are We Going?
AML: Where Are We Now and Where Are We Going?
Catherine Lai, MD, MPH
Role of Immunotherapy in Myeloma
Role of Immunotherapy in Myeloma
Saad Z. Usmani, MD, MBA, FACP
Update on Novel Therapies for NHL
Update on Novel Therapies for NHL
Julie M. Vose, MD, MBA
ALK, ROS-1, RET and MET
ALK, ROS-1, RET and MET
Raja Mudad, MD, FACP
EGFR and Resistant Mechanisms
EGFR and Resistant Mechanisms
Edgardo Santos, MD, FACP
Head and Neck Cancers
Head and Neck Cancers
Cesar Perez, MD
Targeted Therapy for Ovarian and Uterine Tumors
Targeted Therapy for Ovarian and Uterine Tumors
Alexander Olawaiye, MD, FRCOG, FACOG, FACS
Liquid Biopsy
Liquid Biopsy
Christian Rolfo MD, PhD, MBA, Dr.Hc.
Anticoagulation in the Oncology Patient
Anticoagulation in the Oncology Patient
Pamela B. Dudkiewicz, DNP, ARNP-BC, AOCNP
How Far Have We Gone with Biosimilars?
How Far Have We Gone with Biosimilars?
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE